

LIFE HEALTHCARE GROUP HOLDINGS LIMITED

(Incorporated in the Republic of South Africa)

Registration number: 2003/002733/06

Income tax number: 9387/307/15/1

ISIN: ZAE000145892

JSE and A2X share code: LHC

(Life Healthcare, the Group or the Company)

LIFE HEALTHCARE FUNDING LIMITED

(Incorporated in the Republic of South Africa with limited liability)

Registration number: 2016/273566/06

LEI: 3789SJPQJZF8ZYXTZ394

Bond company code: LHF1

(Life Healthcare Funding)

SUMMARISED GROUP RESULTS FOR THE YEAR ENDED 30 SEPTEMBER 2024 AND CASH DIVIDENDS DECLARATION

- Good growth in Group revenue of 12.7%, driven by robust activity growth in southern Africa and excellent growth in NeuraCeq[®] doses sold.
- Paid patient days (PPD) in acute hospitals growing by 1.6%.
- Concluded a transaction to sub-license of one of Life Molecular Imaging's (LMI) early-stage novel products (RM2) for USD 36 million (R664 million). Strong growth of 91.9% in NeuraCeq[®] doses sold.
- The Group concluded the disposal of Alliance Medical Group (AMG) on 31 January 2024 and received R10.2 billion in net cash proceeds after the settlement of all offshore debt and transaction costs. A special dividend of R6.0 per share (R8.8 billion) was paid on 8 April 2024 from these proceeds.
- The Board has declared a final cash dividend of 31.0 cents per share, an increase of 14.8% over prior year and a special dividend of 70.0 cents per share. Total distributions for the year, including special dividends amount to R10.6 billion.

	2024	2023	%
			change
Group revenue from continuing operations (R'm)	25 519	22 641	12.7
Weighted average number of shares (million)	1 443	1 442	0.1
From continuing and discontinued operations			
Earnings per share (EPS) (cents)	328.8	18.3	>1 000
Headline earnings per share (HEPS) (cents)	152.9	88.2	73.4
From continuing operations			
EPS (cents)	137.8	87.0	58.4
HEPS (cents)	139.0	87.5	58.9
Normalised EPS (NEPS) (cents)	132.3	89.1	48.5
Final dividend per share (cents)	31.0	27.0	14.8
Special dividend per share (cents)	70.0	-	

EPS, HEPS and NEPS

Total EPS (from continuing and discontinued operations) increased to 328.8 cents (2023: 18.3 cents) mainly due to the R2.8 billion once-off gain recognised following the completion of the AMG disposal (2023: loss recognised of R990 million). Total HEPS increased by 73.4% to 152.9 cents (2023: 88.2 cents).

NEPS, which excludes non-trading related items, increased by 48.5% to 132.3 cents (2023: 89.1 cents). The LMI RM2 transaction contributed 30.1 cents net after tax. The presentation of normalised earnings metrics are non-IFRS measures.

Financial position and liquidity

The Group is in a strong financial position as at 30 September 2024 with net debt to normalised EBITDA (as per bank covenant definitions) of 0.45 times, well within our covenant of 3.5 times (2.0 times reported at 30 September 2023).

Cash dividend

Final dividend

The Board approved a final gross cash dividend of 31.00 cents per ordinary share. The dividend has been declared from income reserves and is subject to South African dividend withholding tax of 20%, which will be applicable to all shareholders not exempt therefrom, after deduction of which the net cash dividend is 24.80 cents per share.

The Company's total number of issued ordinary shares is 1 467 349 162 as at 26 November 2024.

The Company's income tax reference number is 9387/307/15/1.

In compliance with the requirements of the JSE, the following salient dates are applicable:

Last date to trade cum dividend	Tuesday, 10 December 2024
Shares trade ex the dividend	Wednesday, 11 December 2024
Record date	Friday, 13 December 2024
Payment date	Tuesday, 17 December 2024

Share certificates may not be dematerialised or rematerialised between Wednesday, 11 December 2024 and Friday, 13 December 2024, both days inclusive.

Special dividend

The Board approved a special gross cash dividend of 70.00 cents per ordinary share. The dividend has been declared from income reserves and is subject to South African dividend withholding tax of 20%, which will be applicable to all shareholders not exempt therefrom, after deduction of which the net cash dividend is 56.00 cents per share.

The Company's total number of issued ordinary shares is 1 467 349 162 as at 26 November 2024.

The Company's income tax reference number is 9387/307/15/1.

In compliance with the requirements of the JSE, the following salient dates are applicable:

Finalisation date	Monday, 30 December 2024
Last date to trade cum dividend	Tuesday, 7 January 2025
Shares trade ex the dividend	Wednesday, 8 January 2025
Record date	Friday, 10 January 2025
Payment date	Monday, 13 January 2025

Share certificates may not be dematerialised or rematerialised between Wednesday, 8 January 2025 and Friday, 10 January 2025, both days inclusive.

2025 Outlook

For the 12 months to 30 September 2025 (FY2025) the southern African business will continue to grow its underlying asset base adding 55 acute hospital beds, 24 acute rehabilitation beds and starting the build of a new Life Healthcare acute hospital in the Western Cape (140 beds). The Group will continue to grow its imaging business with further transactions expected to be completed in FY2025 and with further expansion in its nuclear medicine business. The Group will look to complete the Fresenius Medical Care (FMC) Namibia and Eswatini renal transactions in FY2025.

The southern African business will look to drive occupancies to 70% with PPD growth expected to be between 1% and 1.5%.

The southern African business will continue to optimise its underlying asset portfolio, further embed the FMC SA renal operations and focus on operational efficiencies.

For LMI, we expect sales of NeuraCeq® to continue to grow strongly (c. 50%). LMI will continue to try and maximise the product pipeline as well as sustaining the research and development supplies and services business.

Capex for FY2025 is expected to be R2.6 billion.

Audit opinion

The Group has issued its audited annual financial statements for the year ended 30 September 2024. Deloitte & Touche, the Group's independent auditor, has audited the consolidated and separate annual financial statements and has expressed an unmodified audit opinion thereon.

Thanks

The Group's ability to effectively respond to operational challenges, while continuing to provide quality care to its patients, is largely due to the resilience, dedication and unwavering support of its employees, doctors and other healthcare professionals. Life Healthcare would like to thank them for their tireless work and for the care they deliver.

Results announcement

This results announcement is a summary of the information contained in the long-form results announcement and the detailed audited consolidated annual financial statements published on 26 November 2024 and does not contain full or complete details.

The results and the detailed audited consolidated annual financial statements approved on 25 November 2024 are available on Life Healthcare's website (<https://www.lifehealthcare.co.za/investor-relations/results-and-reports/>) and through the JSE cloudlink at <https://senspdf.jse.co.za/documents/2024/JSE/ISSE/LHC/Final24.pdf>

Any investment decisions by shareholders, noteholders and/or investors should be based on a consideration of the audited annual financial statements as a whole and shareholders, noteholders and/or investors are encouraged to review the audited annual financial statements, which is available for viewing on the links as set out above.

The contents of this results announcement are the responsibility of Life Healthcare's board of directors and it has not been reviewed nor audited by Group's auditors.

Non-executive directors: Dr VL Litlhakanyane (Chairman), Dr MF Abdullah, Dr JE Bolger, Dr RA Campbell, Ms CM Henry, Mr LE Holmqvist, Prof ME Jacobs, Mr TP Moeketsi, Ms AM Mothupi, Mr JK Netshitenzhe, Adv M Sello, and Mr F Tonelli

Executive directors: Mr PG Wharton-Hood (Chief Executive), Mr PP van der Westhuizen (Chief Financial Officer)

Company Secretary: Ms J Ranchhod

Registered Office: Oxford Parks, 203 Oxford Road (cnr Eastwood and Oxford Roads), Dunkeld, 2196

Equity Sponsor: Rand Merchant Bank, a division of FirstRand Bank Limited. 1 Merchant Place, cnr Fredman Drive and Rivonia Road, Sandton, 2196

Debt Sponsor: FirstRand Bank Limited. 4 Merchant Place, Corner Fredman Drive and Rivonia Road, Sandton, 2196

Note regarding forward-looking statements: Any forward-looking statements or projections made by the Company, including those made in this announcement, are subject to risk and uncertainties that may cause actual results to differ materially from those projected, are the responsibility of the directors and have not been reviewed or reported on by the Group's external auditors.

Date: 26 November 2024